The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study.
Détails
ID Serval
serval:BIB_7542D67528C1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study.
Périodique
HIV medicine
Collaborateur⸱rice⸱s
EuroSIDA study group
Contributeur⸱rice⸱s
Harxhi A., Losso M., Kundro M., Schmied B., Zangerle R., Karpov I., Vassilenko A., Mitsura V.M., Paduto D., Clumeck N., De Wit S., Delforge M., Florence E., Vandekerckhove L., Hadziosmanovic V., Begovac J., Machala L., Sedlacek D., Kronborg G., Gerstoft J., Katzenstein T., Pedersen C., Johansen I.S., Ostergaard L., Wiese L., Moller N.F., Nielsen L.N., Zilmer K., Smidt J., Aho I., Lacombe K., Pradier C., Fontas E., Rockstroh J., Behrens G., Hoffmann C., Stellbrink H.J., Stefan C., Bogner J., Fätkenheuer G., Chkhartishvili N., Sambatakou H., Adamis G., Paissios N., Szlávik J., Gottfredsson M., Devitt E., Tau L., Turner D., Burke M., Shahar E., Wattad L.M., Elinav H., Haouzi M., Elbirt D., D'Arminio Monforte A., Esposito R., Mazeu I., Mussini C., Mazzotta F., Gabbuti A., Lazzarin A., Castagna A., Gianotti N., Galli M., Ridolfo A., Uzdaviniene V., Matulionyte R., Staub T., Hemmer R., Dragas S., Stevanovic M., Vd Valk M., Trajanovska J., Reikvam D.H., Maeland A., Bruun J., Szetela B., Inglot M., Flisiak R., Grzeszczuk A., Parczewski M., Maciejewska K., Aksak-Was B., Mularska E., Jablonowska E., Kamerys J., Wojcik K., Mozer-Lisewska I., Rozplochowski B., Mansinho K., Radoi R., Oprea C., Gusev D., Trofimova T., Khromova I., Borodulina E., Ranin J., Tomazic J., Miró J.M., Laguno M., Martinez E., Garcia F., Blanco J.L., Martinez-Rebollar M., Mallolas J., Callau P., Rojas J., Inciarta A., Moreno S., Del Campo S., Clotet B., Jou A., Paredes R., Puig J., Santos J.R., Gutierrez M., Mateo G., Sambeat M.A., Laporte J.M., Svedhem V., Thalme A., Sönnerborg A., Brännström J., Flamholc L., Kusejko K., Braun D., Calmy A., Furrer H., Battegay M., Schmid P., Kuznetsova A., Sluzhynska M., Johnson A.M., Simons E., Edwards S., Phillips A., Johnson M.A., Orkin C., Winston A., Clarke A., Leen C., Karpov I., Losso M., Lundgren J., Rockstroh J., Aho I., Rasmussen L.D., Svedhem V., Pradier C., Chkhartishvili N., Matulionyte R., Oprea C., Kowalska J.D., Begovac J., Miró J.M., Guaraldi G., Paredes R., Paredes R., Larsen J.F., Bojesen A., Neesgaard B., Jaschinski N., Fursa O., Sather M., Raben D., Hansen E.V., Kristensen D., Fischer A.H., Jensen S.K., Elsing T.W., Phillips A., Reekie J., Cozzi-Lepri A., Amele S., Pelchen-Matthews A., Roen A., Tusch E.S., Bannister W.
ISSN
1468-1293 (Electronic)
ISSN-L
1464-2662
Statut éditorial
Publié
Date de publication
07/2022
Peer-reviewed
Oui
Volume
23
Numéro
6
Pages
585-598
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH).
All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit.
Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94-8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47-12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00-1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00-1.89) and NHL (aIRR 2.57; 95% CI 1.16-5.68). There was no significant association between HBV and lung or anal cancer.
We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit.
Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94-8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47-12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00-1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00-1.89) and NHL (aIRR 2.57; 95% CI 1.16-5.68). There was no significant association between HBV and lung or anal cancer.
We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
Mots-clé
DNA, Viral, HIV Infections/complications, Hepatitis B/complications, Hepatitis B/epidemiology, Hepatitis B Surface Antigens, Hepatitis B virus/genetics, Hepatitis B, Chronic/complications, Hepatitis B, Chronic/epidemiology, Humans, Neoplasms/complications, HBV DNA, hepatitis B, nonliver cancer
Pubmed
Web of science
Open Access
Oui
Création de la notice
17/12/2021 18:30
Dernière modification de la notice
22/07/2022 6:38
Données d'usage
